We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Acadia Healthcare (ACHC) Q3 Earnings, Revenues Lag Estimates
Read MoreHide Full Article
Acadia Healthcare Company Inc. (ACHC - Free Report) reported third-quarter 2017 adjusted earnings of 58 cents per share, missing the Zacks Consensus Estimate by 10.8%. Moreover, earnings remained flat year over year.
During the reported quarter, the company witnessed better performance with respect to its U.S. operations, despite the substantial impact from the unprecedented hurricane activity, which lowered the quarter’s earnings by 2 cents per diluted share.
The results of the third quarter were primarily affected by the divestiture of 22 facilities in the U.K. as of Nov 30, 2016.
Acadia Healthcare Company, Inc. Price, Consensus and EPS Surprise
Acadia Healthcare’s revenues for the third quarter declined 2.4% to $716.7 million from the prior-year quarter, missing the Zacks Consensus Estimate by 1.5%. The decline could be attributed to higher provision for doubtful accounts.
Same facility revenues increased 5.5%, with a 3.5% increase in patient days and a 1.9% increase in revenue per patient day.
The same facility revenue growth can be attributed to the addition of more than 600 new beds to existing facilities in the 12 months ended Sep 30, 2017. To existing facilities, 179 new beds were added. The company anticipates to add 800 new beds to existing facilities and de novo facilities in 2017.
U.S. same facility revenues were up 6.3% from the year-ago quarter. The company also recorded a 4.2% increase in patient days from 2016.
U.K. same facility revenues inched up 3.8% year over year to $236.4 million. The number of patient days rose 2.5% from the year-ago quarter.
We note that revenues per patient day were up approximately 2% in the United States and rose 1.3% in the U.K.
Total expenses declined nearly 23% year over year to $655.3 million due to lower salaries, wages and benefits, supplies, interest expenses, as well as rents and leases.
Financial Update
Cash and cash equivalents as of Sep 30, 2017 were $75.7 million, up 32.6% from year-end 2016.
Long-term debt was $3.2 billion as of Sep 30, 2017, down 0.6% from the 2016-end level.
Net cash provided by operating activities for the nine months ended Sep 30, 2017 was $271.3 million, up 4.5%, compared to the same period in 2016.
2017 Guidance
The company expects adjusted earnings per diluted share between $2.23 and $2.25 on revenues of $2.82-$2.83 billion.
Adjusted EBITDA is expected between $600 million and $605 million.
The company expects an exchange rate of $1.28 per British Pound Sterling and a tax rate of about 25%.
Zacks Rank
Acadia Healthcare currently carries a Zacks Rank #4 (Sell).
Performance of Other Companies from the Medical Sector
Among the other firms in the medical sector that have reported their third-quarter earnings so far, the bottom line of Centene Corp. (CNC - Free Report) , Quest Diagnostics Incorporated (DGX - Free Report) and UnitedHealth Group Inc. (UNH - Free Report) beat their respective Zacks Consensus Estimate.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Image: Bigstock
Acadia Healthcare (ACHC) Q3 Earnings, Revenues Lag Estimates
Acadia Healthcare Company Inc. (ACHC - Free Report) reported third-quarter 2017 adjusted earnings of 58 cents per share, missing the Zacks Consensus Estimate by 10.8%. Moreover, earnings remained flat year over year.
During the reported quarter, the company witnessed better performance with respect to its U.S. operations, despite the substantial impact from the unprecedented hurricane activity, which lowered the quarter’s earnings by 2 cents per diluted share.
The results of the third quarter were primarily affected by the divestiture of 22 facilities in the U.K. as of Nov 30, 2016.
Acadia Healthcare Company, Inc. Price, Consensus and EPS Surprise
Acadia Healthcare Company, Inc. Price, Consensus and EPS Surprise | Acadia Healthcare Company, Inc. Quote
Quarter Details
Acadia Healthcare’s revenues for the third quarter declined 2.4% to $716.7 million from the prior-year quarter, missing the Zacks Consensus Estimate by 1.5%. The decline could be attributed to higher provision for doubtful accounts.
Same facility revenues increased 5.5%, with a 3.5% increase in patient days and a 1.9% increase in revenue per patient day.
The same facility revenue growth can be attributed to the addition of more than 600 new beds to existing facilities in the 12 months ended Sep 30, 2017. To existing facilities, 179 new beds were added. The company anticipates to add 800 new beds to existing facilities and de novo facilities in 2017.
U.S. same facility revenues were up 6.3% from the year-ago quarter. The company also recorded a 4.2% increase in patient days from 2016.
U.K. same facility revenues inched up 3.8% year over year to $236.4 million. The number of patient days rose 2.5% from the year-ago quarter.
We note that revenues per patient day were up approximately 2% in the United States and rose 1.3% in the U.K.
Total expenses declined nearly 23% year over year to $655.3 million due to lower salaries, wages and benefits, supplies, interest expenses, as well as rents and leases.
Financial Update
Cash and cash equivalents as of Sep 30, 2017 were $75.7 million, up 32.6% from year-end 2016.
Long-term debt was $3.2 billion as of Sep 30, 2017, down 0.6% from the 2016-end level.
Net cash provided by operating activities for the nine months ended Sep 30, 2017 was $271.3 million, up 4.5%, compared to the same period in 2016.
2017 Guidance
The company expects adjusted earnings per diluted share between $2.23 and $2.25 on revenues of $2.82-$2.83 billion.
Adjusted EBITDA is expected between $600 million and $605 million.
The company expects an exchange rate of $1.28 per British Pound Sterling and a tax rate of about 25%.
Zacks Rank
Acadia Healthcare currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Performance of Other Companies from the Medical Sector
Among the other firms in the medical sector that have reported their third-quarter earnings so far, the bottom line of Centene Corp. (CNC - Free Report) , Quest Diagnostics Incorporated (DGX - Free Report) and UnitedHealth Group Inc. (UNH - Free Report) beat their respective Zacks Consensus Estimate.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>